Effects of PPAR-γ agonists on oral cancer cell lines: Potential horizons for chemopreventives and adjunctive therapies.

15-deoxy-D12,14-prostaglandin J2 (15-PGJ2) Ciglitazone NF-κB PPAR-γ squamous cell carcinoma

Journal

Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541

Informations de publication

Date de publication:
09 2020
Historique:
received: 06 01 2020
revised: 17 04 2020
accepted: 12 05 2020
pubmed: 11 6 2020
medline: 22 6 2021
entrez: 11 6 2020
Statut: ppublish

Résumé

Peroxisome proliferator-activated receptor-gamma (PPAR-γ) activators have anti-cancer effects. Our objective was to determine the effect of PPAR-γ ligands 15-deoxy-D NA and CA9-22 cells were treated in vitro with 15-PGJ MTT assays demonstrated dose-dependent decreases after 15-PGJ Our results suggest these agents, in addition to activating PPAR-γ, can downregulate NF-κB and potentiate apoptosis in oral cancer cells.

Sections du résumé

BACKGROUND
Peroxisome proliferator-activated receptor-gamma (PPAR-γ) activators have anti-cancer effects. Our objective was to determine the effect of PPAR-γ ligands 15-deoxy-D
METHODS
NA and CA9-22 cells were treated in vitro with 15-PGJ
RESULTS
MTT assays demonstrated dose-dependent decreases after 15-PGJ
CONCLUSIONS
Our results suggest these agents, in addition to activating PPAR-γ, can downregulate NF-κB and potentiate apoptosis in oral cancer cells.

Identifiants

pubmed: 32519370
doi: 10.1002/hed.26286
pmc: PMC7657659
mid: NIHMS1621744
doi:

Substances chimiques

PPAR gamma 0
Prostaglandin D2 RXY07S6CZ2

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2542-2554

Subventions

Organisme : NCI NIH HHS
ID : P30 CA077598
Pays : United States

Informations de copyright

© 2020 Wiley Periodicals, Inc.

Références

Laryngoscope. 2010 Aug;120(8):1609-13
pubmed: 20564670
Proc Natl Acad Sci U S A. 1993 Feb 15;90(4):1440-4
pubmed: 8381967
Carcinogenesis. 2006 Mar;27(3):619-30
pubmed: 16219633
Biochem Biophys Res Commun. 2000 Apr 13;270(2):400-5
pubmed: 10753637
Cancer Prev Res (Phila). 2017 Feb;10(2):124-132
pubmed: 27993834
Carcinogenesis. 2009 Dec;30(12):2095-9
pubmed: 19861651
J Pharmacol Exp Ther. 1976 May;197(2):391-401
pubmed: 944773
Int J Hyperthermia. 2004 Mar;20(2):240-9
pubmed: 15195518
Br J Cancer. 2002 Dec 2;87(12):1396-403
pubmed: 12454768
Cancer Prev Res (Phila). 2019 Oct;12(10):721-730
pubmed: 31308004
Pharmacol Rev. 2006 Dec;58(4):726-41
pubmed: 17132851
Am J Ther. 1995 Nov;2(11):850-857
pubmed: 11854798
Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):1075-83
pubmed: 14575839
Cancer Prev Res (Phila). 2017 Feb;10(2):116-123
pubmed: 28052934
Int J Oncol. 2001 Sep;19(3):465-71
pubmed: 11494023
Biochem Biophys Res Commun. 2001 Sep 28;287(3):727-32
pubmed: 11563856
Head Neck. 1998 Jul;20(4):334-49
pubmed: 9588707
Cell Growth Differ. 2000 Jan;11(1):49-61
pubmed: 10672903
Pharmacoepidemiol Drug Saf. 2015 Mar;24(3):223-7
pubmed: 25515780
Nature. 1992 Aug 27;358(6389):771-4
pubmed: 1324435
Oncology (Williston Park). 1999 Oct;13(10 Suppl 5):55-60
pubmed: 10550827
Cell Growth Differ. 1995 May;6(5):485-92
pubmed: 7647031
Mol Carcinog. 1999 Oct;26(2):119-29
pubmed: 10506755
Mol Carcinog. 2017 Jan;56(1):149-162
pubmed: 26999671
Br J Cancer. 2000 Nov;83(10):1394-400
pubmed: 11044367
Cancer Res. 2000 Feb 15;60(4):1129-38
pubmed: 10706135
Int J Cancer. 2005 May 1;114(5):806-16
pubmed: 15609302
Diabetes Metab. 2001 Jun;27(3):305-13
pubmed: 11431595
Cancer Res. 1986 Jan;46(1):414-6
pubmed: 2998610
FEBS Lett. 2001 Jul 13;501(1):24-30
pubmed: 11457450
Otolaryngol Head Neck Surg. 2005 Nov;133(5):695-701
pubmed: 16274795
Nature. 2000 Jan 6;403(6765):103-8
pubmed: 10638762
Exp Cell Res. 2007 Oct 1;313(16):3446-58
pubmed: 17707368
J Clin Oncol. 2007 Apr 20;25(12):1476-81
pubmed: 17442990
Int J Mol Sci. 2019 Jun 03;20(11):
pubmed: 31163649
Adv Exp Med Biol. 1997;400B:811-8
pubmed: 9547633
Carcinogenesis. 1999 Oct;20(10):1905-11
pubmed: 10506103
Cancer Sci. 2003 Apr;94(4):365-71
pubmed: 12824906
Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):851-9
pubmed: 7960987
Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4844-9
pubmed: 10781090
Oncologist. 2010;15(9):994-1001
pubmed: 20798198
Mol Carcinog. 2011 Sep;50(9):668-79
pubmed: 21480395
Clin Cancer Res. 2009 Jan 1;15(1):2-8
pubmed: 19118026
Mol Cell Endocrinol. 1994 Apr;100(1-2):149-53
pubmed: 8056148
Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8806-11
pubmed: 9671760
Exp Cell Res. 2017 Apr 15;353(2):63-71
pubmed: 28219679
J Clin Oncol. 2001 Feb 1;19(3):800-11
pubmed: 11157034
Curr Diab Rep. 2017 Apr;17(4):21
pubmed: 28293908

Auteurs

Jeffrey A Hall (JA)

Ohio Health Group, Columbus, Ohio, USA.

Mark Rusten (M)

SoutheastHEALTH, Cape Girardeau, Missouri, USA.

Raed D Abughazaleh (RD)

Department of Otolaryngology-Head and Neck Surgery, University of Minnesota, Minneapolis, Minnesota, USA.

Beverly Wuertz (B)

Department of Otolaryngology-Head and Neck Surgery, University of Minnesota, Minneapolis, Minnesota, USA.

Vannesa Souksavong (V)

University of Minnesota Medical School, University of Minnesota, Minneapolis, Minnesota, USA.

Paul Escher (P)

University of Minnesota Medical School, University of Minnesota, Minneapolis, Minnesota, USA.

Frank Ondrey (F)

Department of Otolaryngology-Head and Neck Surgery, University of Minnesota, Minneapolis, Minnesota, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH